{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T04:19:10Z","timestamp":1788668350180,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T00:00:00Z","timestamp":1702252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s12072-023-10616-8","type":"journal-article","created":{"date-parts":[[2023,12,11]],"date-time":"2023-12-11T12:03:57Z","timestamp":1702296237000},"page":"540-549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Incidence and predictors of hepatocellular carcinoma in NAFLD without diagnosed cirrhosis: a nationwide real-world U.S. study"],"prefix":"10.1007","volume":"18","author":[{"given":"Daniel Q.","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sally","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biyao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee Hui","family":"Yeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramsey","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-4989","authenticated-orcid":false,"given":"Mindie H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,11]]},"reference":[{"issue":"5","key":"10616_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(5):389\u2013398","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10616_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384","journal-title":"Hepatology"},{"issue":"12","key":"10616_CR3","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(12):2809\u201317.e28","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10616_CR4","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","volume":"69","author":"C Estes","year":"2018","unstructured":"Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016\u20132030. J Hepatol. 2018;69(4):896\u2013904","journal-title":"J Hepatol"},{"issue":"10","key":"10616_CR5","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u20132564","journal-title":"Cell"},{"issue":"4","key":"10616_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100305","volume":"3","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Henry L. Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma. JHEP Rep. 2021;3(4): 100305","journal-title":"JHEP Rep"},{"issue":"9","key":"10616_CR7","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S2468-1253(23)00157-7","volume":"8","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Noureddin N, Ajmera V, Amangurbanova M, Bettencourt R, Truong E, et al. Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(9):829\u2013836","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10616_CR8","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1002\/hep.32758","volume":"77","author":"DJH Tan","year":"2023","unstructured":"Tan DJH, Setiawan VW, Ng CH, Lim WH, Muthiah MD, Tan EX, et al. Global burden of liver cancer in males and females: changing etiological basis and the growing contribution of NASH. Hepatology. 2023;77(4):1150\u20131163. https:\/\/doi.org\/10.1002\/hep.32758","journal-title":"Hepatology"},{"issue":"6","key":"10616_CR9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Terrault NA, Tacke F, Gluud LL, Arrese M, Bugianesi E, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388\u2013398","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10616_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1053\/j.gastro.2023.04.025","volume":"165","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Wilson LA, Behling C, Kleiner DE, Kowdley KV, Dasarathy S, et al. Fibrosis progression rate in biopsy-proven nonalcoholic fatty liver disease among people with diabetes versus people without diabetes: a multicenter study. Gastroenterology. 2023;165(2):463\u201372.e5","journal-title":"Gastroenterology"},{"issue":"4","key":"10616_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","volume":"18","author":"DQ Huang","year":"2021","unstructured":"Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18(4):223\u2013238","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10616_CR12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.cmet.2022.05.003","volume":"34","author":"DQ Huang","year":"2022","unstructured":"Huang DQ, Singal AG, Kono Y, Tan DJH, El-Serag HB, Loomba R. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer. Cell Metab. 2022;34(7):969\u201377.e2","journal-title":"Cell Metab"},{"issue":"8","key":"10616_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/apt.15673","volume":"51","author":"C Estes","year":"2020","unstructured":"Estes C, Chan HLY, Chien RN, Chuang WL, Fung J, Goh GB, et al. Modelling NAFLD disease burden in four Asian regions-2019-2030. Aliment Pharmacol Ther. 2020;51(8):801\u2013811","journal-title":"Aliment Pharmacol Ther"},{"key":"10616_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.05.019","author":"JH Koh","year":"2023","unstructured":"Koh JH, Ng CH, Nah B, Tan DJH, Loomba R, Huang DQ. NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2023.05.019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10616_CR15","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/apt.14937","volume":"48","author":"JG Stine","year":"2018","unstructured":"Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, et al. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7):696\u2013703","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10616_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","volume":"23","author":"DJH Tan","year":"2022","unstructured":"Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, et al. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. Lancet Oncol. 2022;23(4):521\u2013530","journal-title":"Lancet Oncol"},{"issue":"1","key":"10616_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u2013380","journal-title":"Hepatology"},{"issue":"1","key":"10616_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"EASL Clinical Practice Guidelines","year":"2018","unstructured":"EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236","journal-title":"J Hepatol"},{"issue":"6","key":"10616_CR19","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1053\/j.gastro.2019.12.053","volume":"158","author":"R Loomba","year":"2020","unstructured":"Loomba R, Lim JK, Patton H, El-Serag HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology. 2020;158(6):1822\u20131830","journal-title":"Gastroenterology"},{"key":"10616_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00818-8","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Singal AG, Kanwal F, Lampertico P, Buti M, Sirlin CB, et al. Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology. Nat Rev Gastroenterol Hepatol. 2023. https:\/\/doi.org\/10.1038\/s41575-023-00818-8","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"10616_CR21","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1002\/hep.29363","volume":"66","author":"S Augustin","year":"2017","unstructured":"Augustin S, Pons M, Maurice JB, Bureau C, Stefanescu H, Ney M, et al. Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. Hepatology. 2017;66(6):1980\u20131988","journal-title":"Hepatology"},{"issue":"6","key":"10616_CR22","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","volume":"155","author":"F Kanwal","year":"2018","unstructured":"Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828\u201337.e2","journal-title":"Gastroenterology"},{"issue":"10","key":"10616_CR23","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104\u20131112","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10616_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cgh.2021.05.002","volume":"20","author":"LA Orci","year":"2022","unstructured":"Orci LA, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, et al. Incidence of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. Clin Gastroenterol Hepatol. 2022;20(2):283\u201392.e10","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10616_CR25","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1002\/hep.24199","volume":"53","author":"J Bruix","year":"2011","unstructured":"Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020\u20131022","journal-title":"Hepatology"},{"issue":"3","key":"10616_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/hep.32185","volume":"75","author":"AG Singal","year":"2022","unstructured":"Singal AG, Tayob N, Mehta A, Marrero JA, El-Serag H, Jin Q, et al. GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. 2022;75(3):541\u2013549","journal-title":"Hepatology"},{"issue":"1","key":"10616_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jhep.2022.08.036","volume":"78","author":"ND Parikh","year":"2023","unstructured":"Parikh ND, Tayob N, Singal AG. Blood-based biomarkers for hepatocellular carcinoma screening: approaching the end of the ultrasound era? J Hepatol. 2023;78(1):207\u2013216","journal-title":"J Hepatol"},{"issue":"5834","key":"10616_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1126\/science.1140485","volume":"317","author":"WE Naugler","year":"2007","unstructured":"Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121\u2013124","journal-title":"Science"},{"issue":"1","key":"10616_CR29","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2004.09.012","volume":"42","author":"LA Adams","year":"2005","unstructured":"Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42(1):132\u2013138","journal-title":"J Hepatol"},{"issue":"1","key":"10616_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","volume":"17","author":"M Alexander","year":"2019","unstructured":"Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, Ansell D, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019;17(1):95","journal-title":"BMC Med"},{"issue":"5","key":"10616_CR31","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/hep.31845","volume":"74","author":"TG Simon","year":"2021","unstructured":"Simon TG, Roelstraete B, Sharma R, Khalili H, Hagstr\u00f6m H, Ludvigsson JF. Cancer risk in patients with biopsy-confirmed nonalcoholic fatty liver disease: a population-based cohort study. Hepatology. 2021;74(5):2410\u20132423","journal-title":"Hepatology"},{"issue":"1","key":"10616_CR32","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113\u2013121","journal-title":"Gastroenterology"},{"issue":"4","key":"10616_CR33","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.dld.2018.12.014","volume":"51","author":"A Lonardo","year":"2019","unstructured":"Lonardo A, Ballestri S, Mantovani A, Nascimbeni F, Lugari S, Targher G. Pathogenesis of hypothyroidism-induced NAFLD: evidence for a distinct disease entity? Dig Liver Dis. 2019;51(4):462\u2013470","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10616_CR34","doi-asserted-by":"publisher","first-page":"347","DOI":"10.14218\/JCTH.2020.00027","volume":"8","author":"T Kizivat","year":"2020","unstructured":"Kizivat T, Maric I, Mudri D, Curcic IB, Primorac D, Smolic M. Hypothyroidism and nonalcoholic fatty liver disease: pathophysiological associations and therapeutic implications. J Clin Transl Hepatol. 2020;8(3):347\u2013353","journal-title":"J Clin Transl Hepatol"},{"issue":"11","key":"10616_CR35","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.tem.2022.08.001","volume":"33","author":"E Hatziagelaki","year":"2022","unstructured":"Hatziagelaki E, Paschou SA, Sch\u00f6n M, Psaltopoulou T, Roden M. NAFLD and thyroid function: pathophysiological and therapeutic considerations. Trends Endocrinol Metab. 2022;33(11):755\u2013768","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10616_CR36","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.cgh.2006.07.011","volume":"5","author":"A Reddy","year":"2007","unstructured":"Reddy A, Dash C, Leerapun A, Mettler TA, Stadheim LM, Lazaridis KN, et al. Hypothyroidism: a possible risk factor for liver cancer in patients with no known underlying cause of liver disease. Clin Gastroenterol Hepatol. 2007;5(1):118\u2013123","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10616_CR37","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.31014","volume":"71","author":"F Kanwal","year":"2020","unstructured":"Kanwal F, Kramer JR, Li L, Dai J, Natarajan Y, Yu X, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology. 2020;71(3):808\u2013819","journal-title":"Hepatology"},{"issue":"1","key":"10616_CR38","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/bjc.2012.492","volume":"108","author":"F Turati","year":"2013","unstructured":"Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 2013;108(1):222\u2013228","journal-title":"Br J Cancer"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10616-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-023-10616-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-023-10616-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T19:12:03Z","timestamp":1712949123000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-023-10616-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,11]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10616"],"URL":"https:\/\/doi.org\/10.1007\/s12072-023-10616-8","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,11]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MHN: Research funding: Pfizer, Enanta, Gilead, CurveBio, Exact Sciences, Helio Health, Glycotest, National Cancer Institute, B.K. Kee Foundation, Vir Biotech; Consulting: Gilead, Intercept, GSK, Exact Science, Novartis, Janssen, Bayer. RC: Research funding: Gilead, Siemens Healthineers. DQH: Advisory board\/consulting: Gilead. Sally Tran, Scott Barnett, Biyao Zou, Yee Hui Yeo, and Ramsey Cheung declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Review Board at Stanford University, Stanford, California, USA. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}